3분기 라지캡 제약-바이오 기업 매출 성장율 : 네이버 블로그 (2019/11/25)

Name	Symbol	Revene Growth	Revenue	Market Cap
Alexion	ALXN	23.00%	$1.26 B	24.6B
Regeneron	REGN	23.00%	$2.05 B	38.9B
AstraZeneca	AZN	22.00%	$6.13 B	62.9B
Vertex	VRTX	21.00%	$950 M	56.1B
Merck	MERK	16.00%	$12.40 B	1330.6B
Celgene	CELG	16.00%	$4.51 B	77.0B
Novartis	NVS	13.00%	$12.17 B	228.7B
Roche	RHHBY	13.00%	$15.78 B	262.0B
Novo Nordisk	NVO	9.00%	$4.46 B	100.9B
Bristol-Myers Squibb	BMY	6.00%	$6.01 B	132.3B
GlaxoSmithKline	GSK	6.00%	$12.05 B	219.6B
Bayer	BAYRY	5.40%	$10.82 B	17.7B
Johnson & Johnson	JNJ	5.20%	$20.73 B	363.4B
Biogen	BIIB	5.00%	$3.60 B	54.0B
Allergan	AGN	3.50%	$4.05 B	60.3B
Eli Lilly	LLY	3.00%	$5.48 B	111.6B
AbbVie	ABBV	3.00%	$8.48 B	127.3B
Gilead Sciences	GILD	0.00%	$5.52 B	82.6B
Takeda	TAK	-0.20%	$7.47 B	7013.2B
Sanofi	SNY	-1.10%	$10.45 B	58.3B
Amgen	AMGN	-3.00%	$5.74 B	137.1B
Pfizer	PFE	-3.00%	$12.68 B	212.1B
Teva	TEVA	-6.00%	$4.26 B	38.4B

​

원자료 출처: https://www.fiercepharma.com/pharma/astrazeneca-merck-and-novartis-top-pharma-s-q3-growth-rankings?utm_source=internal&utm_medium=rss

 

AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so much

The drug industry faces no shortage of challenges, from pricing threats and payer clampdowns to stepped-up competition and supply shortages. Still, a look at third-quarter numbers shows many top players are rolling right along—though some Big Pharmas weren't so lucky.

www.fiercepharma.com

​